Related Experiment Video
Updated: Mar 9, 2026
Author Spotlight: Investigating the Impact of Aging on Hippocampal-Dependent Spatial Learning
Published on: February 16, 2024
Effect of pregabalin on fear-based conditioned avoidance learning and spatial learning in a mouse model of
Kinga Sałat1, Adrian Podkowa1, Natalia Malikowska1
1a Department of Pharmacodynamics, Faculty of Pharmacy , Jagiellonian University, Medical College , Krakow , Poland.
Objectives:
Cognitive deficits are one of the frequent symptoms accompanying epilepsy or its treatment.
Methods:
In this study, the effect on cognition of intraperitoneally administered antiepileptic drug, pregabalin (10 mg/kg), was investigated in scopolamine-induced memory-impaired mice in the passive avoidance task and Morris water maze task. The effect of scopolamine and pregabalin on animals' locomotor activity was also studied.
Results:
In the retention phase of the passive avoidance task, pregabalin reversed memory deficits induced by scopolamine (p < 0.05). During the acquisition phase of the Morris water maze pregabalin-treated memory-impaired mice performed the test with longer escape latencies than the vehicle-treated mice (significant at p < 0.05 on Day 5, and at p < 0.001 on Day 6). There were no differences in this parameter between the scopolamine-treated control group and pregabalin-treated memory-impaired mice, which indicated that pregabalin had no influence on spatial learning in this task. During the probe trial a significant difference (p < 0.05) was observed in terms of the mean number of target crossings between vehicle-treated mice and pregabalin-treated memory-impaired mice but there was no difference between the scopolamine-treated control group and mice treated with pregabalin + scopolamine. Pregabalin did not influence locomotor activity increased by scopolamine.
Discussion:
In passive avoidance task, pregabalin reversed learning deficits induced by scopolamine. In the Morris water maze, pregabalin did not influence spatial learning deficits induced by scopolamine. These results are relevant for epileptic patients treated with pregabalin and those who use it for other therapeutic indications (anxiety, pain).
